Prostate Cancer | Specialty

Germline Variants Provide Insight Into Tumor Growth in Prostate Cancer

December 5th 2019

Select DNA variants leading to methylation dysregulation within the germline DNA of men with localized prostate cancer were found to be predictive of disease biology, suggesting the prognostic capacity of inherited elements of a patient’s genome, according to data published in Nature Medicine.

Prostate Cancer Treatment Options Expand With ADT Combinations

December 4th 2019

David F. Penson, MD, MPH, MMHC, discusses the current armamentarium and ongoing research in prostate cancer.

Dr. Barocas on the CEASAR Trial in Localized Prostate Cancer

December 4th 2019

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.

Population-Based Study Informs Decision-Making in Localized Prostate Cancer

December 2nd 2019

Daniel A. Barocas, MD, MPH, FACS, discusses the CEASAR study in prostate cancer, as well as therapeutic updates in renal cell carcinoma.

Enzalutamide Gains Approval in China for mCRPC

November 28th 2019

China’s National Medical Products Administration has granted approval to enzalutamide for the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic following progression on androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

Dr. Morris on Safety Profiles of AR Inhibitors in Prostate Cancer

November 27th 2019

David Morris, MD, FACS, discusses the safety profiles and common adverse events related to the androgen receptor inhibitors apalutamide, enzalutamide, and darolutamide for prostate cancer.

Expert Shares Insight on Recent Prostate Cancer Developments

November 27th 2019

Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.

Dr. Penson on Treatment Selection in Metastatic Hormone-Sensitive Prostate Cancer

November 22nd 2019

David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.

Dr. Koo on New Management Strategies for Prostate Cancer

November 21st 2019

Phillip J. Koo, MD, discusses new management strategies for patients with prostate cancer.

Dr. Bryce on Potential Biomarkers of Response to Immunotherapy in Prostate Cancer

November 20th 2019

Alan H. Bryce, MD, discusses potential biomarkers of response to immunotherapy in prostate cancer.

Dr. Chang on the Use of PARP Inhibitors in Prostate Cancer

November 20th 2019

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

Relugolix Elicits High Response Rate in Advanced Prostate Cancer

November 19th 2019

Treatment with relugolix achieved a high rate of sustained testosterone suppression to castrate levels in patients with androgen-sensitive advanced prostate cancer, meeting the primary endpoint of the phase III HERO trial.

Prostate Cancer Consensus Panel to Script Testing Guidelines for Inherited Disease

November 19th 2019

Although the oncology community has made many advancements in understanding the role of germline mutations in prostate cancer, a pressing need exists for clarity in determining which genes should be included in testing panels and what steps should be taken to counsel patients at risk and their families.

PROfound Data Could Lead to First PARP Inhibitor Approval in mCRPC

November 17th 2019

Alan H. Bryce, MD, discusses encouraging updates and emerging strategies in metastatic prostate cancer treatment.

Dr. Sartor on the VISION Trial in mCRPC

November 16th 2019

A. Oliver Sartor, MD, discusses the phase III VISION trial in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

Selecting Among AR-Directed Agents in Nonmetastatic CRPC

November 16th 2019

David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.

Metastatic CSPC: Toxicity Management & Future Treatment

November 14th 2019

The Role of Enzalutamide in Treating Metastatic CSPC

November 14th 2019

The Approval of Apalutamide for Metastatic CSPC

November 14th 2019

The STAMPEDE Trial Long Term Follow-Up Data

November 14th 2019